Aprepitant
- Generic Name
- Aprepitant
- Brand Names
- Aponvie, Cinvanti, Emend
- Drug Type
- Small Molecule
- Chemical Formula
- C23H21F7N4O3
- CAS Number
- 170729-80-3
- Unique Ingredient Identifier
- 1NF15YR6UY
- Background
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substan...
- Indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).
- Associated Conditions
- Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV), Acute delayed Nausea caused by highly emetogenic cancer chemotherapy
- Associated Therapies
- -
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Katy Peters
- Target Recruit Count
- 136
- Registration Number
- NCT01450826
- Locations
- 🇺🇸
The Preston Robert Tisch Brain Tumor Center at Duke, Durham, North Carolina, United States
Aprepitant for Postoperative Nausea and Vomiting in Laparoscopic Hysterectomy
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Gachon University Gil Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT01440673
- Locations
- 🇰🇷
Gil Medical Center Gachon University, Inchon, Korea, Republic of
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-09-12
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Gynecologic Oncology Associates
- Target Recruit Count
- 20
- Registration Number
- NCT01432015
- Locations
- 🇺🇸
Gynecologic Oncology Associates, Newport Beach, California, United States
Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2015-01-19
- Target Recruit Count
- 96
- Registration Number
- NCT01402024
- Locations
- 🇮🇳
Dr. BRA IRCH, AIIMS, New Delhi, Delhi, India
Developing Individualized Strategies to Prevent Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT01393288
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Brigham & Women's Hospital, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
- Conditions
- Interventions
- First Posted Date
- 2011-06-20
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 413
- Registration Number
- NCT01376297
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Veterans Administration New Jersey Health Care System, East Orange, New Jersey, United States
🇺🇸East Valley Hematology and Oncology Medical Group, Burbank, California, United States
Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
- First Posted Date
- 2011-04-12
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 41
- Registration Number
- NCT01334086
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 18
- Registration Number
- NCT01300988
- Locations
- 🇺🇸
Clinical Trials Unit. University of Pennsylvania, Philadelphia, Pennsylvania, United States
Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
- First Posted Date
- 2011-02-17
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 212
- Registration Number
- NCT01298193
- Locations
- 🇪🇸
Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
🇪🇸Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2011-01-12
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 4
- Registration Number
- NCT01275664
- Locations
- 🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States
🇺🇸Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.